logo
Plus   Neg
Share
Email

Novartis Issues R&D Update; Plans 60 Major Submissions From 2019 To 2021

Swiss drug major Novartis (NVS) on Monday issued its Research & Development update, highlighting its development pipeline including potential blockbusters and advanced therapy platforms. The company said 60 major submissions are planned from 2019 to 2021.

The company reported 26 potential blockbusters in confirmatory development. There are 13 projects in clinical development across Cell, Gene & Radioligand therapies, and 9 more are expected to enter the clinic in 2019.

Novartis said it is advancing a pipeline of medicines with potential to change the standard of care in high burden disease areas. In multiple sclerosis, Mayzent (siponimod, formerly BAF312) is expected to launch in Q1 2019 as the first and only drug proven to delay progression for typical patients living with SPMS.

Further, the company said maximizing the potential of in-line brands with new data is a key development priority. Novartis is pursuing new indications and building out the data profile for Cosentyx, Entresto and Gilenya.

Cosentyx is expected to be Novartis' largest drug next year, with robust growth in all three approved indications, PSO, PSA and AS. Confidence in Cosentyx comes from 100 studies and an extensive phase III clinical trial program, including PREVENT in non-radiographic axial spondyloarthropathy, a potential fourth indication.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
While reporting financial results for the first quarter, American Express Co. (AXP) on Thursday affirmed its earnings and revenue growth guidance for the full-year 2019. For fiscal 2019, the company continues to project earnings in the range of $7.64 to $8.14 per share and adjusted earnings in the... While reporting financial results for the first quarter, Honeywell international Inc. (HON) on Thursday raised its earnings and sales outlook for the full-year 2019. For fiscal 2019, the company raised its earnings outlook to a range of $7.90 to $8.15 per share from the previous guidance range of... Chipmaker Intel Corp. said it plans to exit the 5G smartphone modem business, with the announcement coming just hours after Apple Inc. and Qualcomm Inc. said they have settled their royalty dispute. The settlement includes a payment from Apple to Qualcomm, but no details were disclosed about the payment or fees. Qualcomm's shares are gaining more than 14 percent in Wednesday's trading session.
Follow RTT